Clinical Trial Update: Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) [Phase 2]

View source ↗

Summary

EXACTLE is a Phase 2 trial evaluating Alpha-1 antitrypsin therapy for emphysema in patients with Alpha-1 antitrypsin deficiency. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Emphysema

Drugs mentioned

• Alpha-1 Antitrypsin (alpha-1 antitrypsin)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2014-08-21